ORIGINAL RESEARCH

Efficacy of commercial bacteriophage products against ESKAPE pathogens

About authors

Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Nikita S. Kuptsov
Malaya Pirogovskaya, 1a, Moscow, 119435; moc.liamg@snvostpuk

About paper

Funding: all study expenses were covered by the funds allocated for the State Assignment on the Development of a personalized approach to the therapy of infections using virulent bacteriophages (Code: Bacteriophage).

Acknowledgements: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, the Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical Biological Agency for their help with bacterial gene sequencing and for subsequent multilocus sequencing typing.

Author contribution: Kuptsov NS — study plan; data acquisition and analysis; manuscript preparation; Kornienko MA — study plan; data analysis; manuscript preparation; Gorodnichev RB, Parfenova TV — data acquisition and analysis; Danilov DI, Malakhova MV — data acquisition; Makarenko GI — sample collection; Shitikov EA — data analysis; manuscript preparation; Ilina EN — manuscript preparation.

Received: 2020-05-06 Accepted: 2020-05-20 Published online: 2020-05-26
|
Fig. 1. Resistance to antibiotics among the strains of K. pneumoniae (A), P. aeruginosa (B), S. aureus (C), and E. faecium (D). The pink shows the proportion of resistant strains. CIP — ciprofloxacin, TET — tetracycline, ERY — erythromycin, MRP — meropenem, VAN — vancomycin, OXA — oxacillin, CTR — ceftriaxone, GEN — gentamicin
Fig. 2. Results of molecular genetic typing for K. pneumonia (A) P. aeruginosa (B) E. faecium (C), and S. aureus (D)
Fig. 3. The efficacy of commercial phage products against K. pneumoniae (A), P. aeruginosa (B) and S. аureus (C). The green shows the proportion of strains sensitive to the tested phage products. Batch numbers represent the tested products: "Purified polyvalent pyobacteriophage" (U1, U25); "Complex pyobacteriophage" (N74, N45); "Klebsiella pneumoniae purified bacteriophage" (P252, P251); "Klebsiella pneumoniae purified polyvalent bacteriophage" (U27); "Pseudomonas aeruginosa bacteriophage" (N7); "Staphylococcal bacteriophage" (P332, N33)
Table 1. Commercial bacteriophage products used in the study